The use of base editing to generate universal off-the-shelf CAR T cells induced durable remissions -- up to 36 months in one ...

At the recent American Society of Hematology annual meeting, researchers presented preclinical data examining how ...

Researchers analyzed the diagnostic value of stereotactic brain biopsy in patients with leukemia presenting central ...

Hematologist-oncologists are doctors who specialize in treating blood cancers such as acute lymphoblastic leukemia (ALL). ALL is a rare, rapidly progressing cancer of the blood and bone marrow. The ...

In most cases, acute lymphoblastic leukemia (ALL) manifests as a de novo malignancy in previously healthy people. Risk factors for developing ALL include age older than 70 years and genetic disorders, ...

Acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) are the most common pediatric cancers and among the leading causes of death in children. To improve kids’ chances of survival, early ...

Oncaspar (pegaspargase) is a long-acting prescription injection medicine used for people with a type of blood cancer known as acute lymphoblastic leukemia (ALL). It is also approved specifically for ...

Supportive care aims to ensure that patients with acute lymphoblastic leukemia (ALL) derive the most benefit from ALL therapy despite the intensive treatments they undergo. Supportive care should be ...